C2i Genomics
Whole-genome Cancer Treatment Intelligence Platform
StartupC2i Genomics is a Tirat Carmel-based startup in the Health Tech & Life Sciences sector, established in 2019. Whole-genome Cancer Treatment Intelligence Platform. The company has raised a total of $113.2M across 3 funding rounds, currently at the Acquired stage. C2i Genomics was founded by Asaf Zviran, Boris Oklander, Ezra Sofer. Key investors include Casdin Capital, Duquesne Family Office, iGlobe Partners, among 9 total investors. The company has 11-50 employees. Core technologies: Platforms & Interfaces, Software, Data Storage, Cloud, Artificial Intelligence, Machine Learning.
With $113.2M in total funding, C2i Genomics is a Acquired-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StageAcquired
- ProductClinical Trial
- ModelB2B
- Employees11-50
- HQTirat Carmel
- DistrictNorth District
- Last Round$100M
- Casdin CapitalLead
- Duquesne Family Office
- iGlobe Partners
9 investors total
Asaf ZviranCo-founder, CEO & CSO
Boris OklanderCo-founder & CTOEzra SoferCo-founder, General Manager and CFO
13 articles covered by sources including www.calcalistech.com,
www.genomeweb.com,
hitconsultant.net,
www.businesswire.com,
www.israel21c.org.
What does C2i Genomics do?
C2i Genomics empowers researchers, physicians, and patients with ultra-sensitive whole-genome cancer detection. Its SaaS solution utilizes a cloud-based platform to perform cancer tumor burden monitoring on a global scale, leveraging the thousands of already installed genome sequencers around the world. Using scientific breakthroughs, growing genomic and clinical databases, and sophisticated signal processing and artificial intelligence, C2i enables high-precision personalized medicine, reduced cancer treatment costs, and accelerated drug development. C2i Genomics provides acuity in cancer detection and monitoring by combining whole genome sequencing with a proprietary AI-based tumor enrichment method that recognizes patient-specific cancer patterns.
How much funding has C2i Genomics raised?
C2i Genomics has raised $113.2M in total funding across 3 rounds. The company is currently at the Acquired stage. Key investors include Casdin Capital, Duquesne Family Office, iGlobe Partners.
Who founded C2i Genomics?
C2i Genomics was founded in 2019 by Asaf Zviran (Co-founder, CEO & CSO), Boris Oklander (Co-founder & CTO), Ezra Sofer (Co-founder, General Manager and CFO).
What sector is C2i Genomics in?
C2i Genomics operates in Health Tech & Life Sciences, Digital Healthcare, Digital Medical Diagnostics, with core technologies in Platforms & Interfaces, Software, Data Storage, Cloud, Artificial Intelligence, Machine Learning. Target customers: Healthcare & Life Sciences, Healthcare, Providers, Insurance Companies, Life Sciences, Pharmaceuticals.
Where is C2i Genomics located?
C2i Genomics is based in Nahum Het Street 5, Haifa, Israel, North District. The company also has offices abroad.